24 May 2013
Keywords: epix, ms-325, clears, second, ph, iii, trial
Article | 17 March 2003
Data from a second Phase III trial of EPIX Medical's blood pool contrastagent, MS-325, have confirmed its utility for detecting ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 March 2003
10 March 2003
23 May 2013
© 2013 thepharmaletter.com